Funds › HighVista Strategies LLC
HighVista Strategies LLC
13F for Q3 2026, filed Nov 13, 2026. 136 positions worth $380.9M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$380.9M
−$57.7M (13.2%) vs Q2 2026
Positions
136
147 in Q2 2026
Top 10 share
27.2%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of HighVista Strategies LLC in the latest 13F quarter?
Using 13F.ai, how has HighVista Strategies LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of HighVista Strategies LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | DBC Invesco DB Commodity Index Tracking Fund · Units | 1.06M | $34.2M | 9.0% | Unchanged | 13F ↗ |
| 2 | RVMD Revolution Medicines, Inc. | 45,897 | $9.4M | 2.5% | -31.5% | 13F ↗ |
| 3 | ABVX Abivax SA · ADR | 87,057 | $8.6M | 2.3% | -23.0% | 13F ↗ |
| 4 | PCVX Vaxcyte, Inc. | 142,107 | $8.1M | 2.1% | -5.1% | 13F ↗ |
| 5 | GMAB Genmab A/S · ADR | 226,098 | $8.1M | 2.1% | New | 13F ↗ |
| 6 | RLAY Relay Therapeutics, Inc. | 409,325 | $7.4M | 1.9% | -19.1% | 13F ↗ |
| 7 | TNGX Tango Therapeutics, Inc. | 287,769 | $7.2M | 1.9% | +10.7% | 13F ↗ |
| 8 | TARS Tarsus Pharmaceuticals, Inc. | 90,432 | $7.1M | 1.9% | +3.9% | 13F ↗ |
| 9 | IMVT Immunovant, Inc. | 205,954 | $7.0M | 1.8% | -25.9% | 13F ↗ |
| 10 | COGT Cogent Biosciences, Inc. | 210,055 | $6.7M | 1.8% | +11.3% | 13F ↗ |
| 11 | LBRX LB Pharmaceuticals Inc | 173,804 | $6.7M | 1.8% | -17.8% | 13F ↗ |
| 12 | MANE Veradermics, Incorporated | 54,232 | $6.6M | 1.7% | New | 13F ↗ |
| 13 | EWTX Edgewise Therapeutics, Inc. | 160,647 | $6.5M | 1.7% | +76.5% | 13F ↗ |
| 14 | ALKS Alkermes plc | 156,763 | $6.4M | 1.7% | -12.5% | 13F ↗ |
| 15 | CMPS COMPASS Pathways Plc · ADR | 508,780 | $6.3M | 1.7% | +37.1% | 13F ↗ |
| 16 | VRDN Viridian Therapeutics, Inc. | 272,610 | $5.6M | 1.5% | +70.5% | 13F ↗ |
| 17 | GPCR Structure Therapeutics Inc. | 170,193 | $5.3M | 1.4% | +30.1% | 13F ↗ |
| 18 | NRIX Nurix Therapeutics, Inc. | 221,026 | $5.2M | 1.4% | +8.5% | 13F ↗ |
| 19 | NVDA NVIDIA Corporation | 21,892 | $5.0M | 1.3% | +0.5% | 13F ↗ |
| 20 | TYRA Tyra Biosciences, Inc. | 227,436 | $5.0M | 1.3% | +23.1% | 13F ↗ |
| 21 | ELVN Enliven Therapeutics, Inc. | 105,319 | $4.8M | 1.3% | -23.6% | 13F ↗ |
| 22 | TLN Talen Energy Corporation | 15,151 | $4.7M | 1.2% | +85.9% | 13F ↗ |
| 23 | SYRE Spyre Therapeutics, Inc. | 50,414 | $4.5M | 1.2% | -35.2% | 13F ↗ |
| 24 | AMLX Amylyx Pharmaceuticals, Inc. | 153,515 | $4.5M | 1.2% | -60.2% | 13F ↗ |
| 25 | DFTX Definium Therapeutics, Inc. | 109,086 | $4.2M | 1.1% | -55.1% | 13F ↗ |
| 26 | AMZN Amazon.com, Inc. | 16,247 | $4.0M | 1.1% | +21.3% | 13F ↗ |
| 27 | PHVS Pharvaris N.V. | 126,174 | $4.0M | 1.1% | -21.4% | 13F ↗ |
| 28 | TVTX Travere Therapeutics, Inc. | 56,538 | $3.3M | 0.9% | -34.4% | 13F ↗ |
| 29 | VERA Vera Therapeutics, Inc. | 101,905 | $3.3M | 0.9% | -3.8% | 13F ↗ |
| 30 | META Meta Platforms, Inc. | 4,512 | $3.3M | 0.9% | +288% | 13F ↗ |
| 31 | MU Micron Technology, Inc. | 3,056 | $3.3M | 0.9% | +143% | 13F ↗ |
| 32 | PRAX Praxis Precision Medicines, Inc. | 11,091 | $3.2M | 0.8% | -63.3% | 13F ↗ |
| 33 | GHRS GH Research PLC | 130,117 | $3.1M | 0.8% | -18.0% | 13F ↗ |
| 34 | ARGX argenx SE · ADR | 3,123 | $3.0M | 0.8% | -31.5% | 13F ↗ |
| 35 | PTGX Protagonist Therapeutics, Inc. | 20,956 | $3.0M | 0.8% | -14.3% | 13F ↗ |
| 36 | CTNM Contineum Therapeutics, Inc. | 217,788 | $2.9M | 0.8% | New | 13F ↗ |
| 37 | CCCC C4 Therapeutics, Inc. | 873,277 | $2.9M | 0.8% | -35.2% | 13F ↗ |
| 38 | UNP Union Pacific Corporation | 10,584 | $2.9M | 0.8% | New | 13F ↗ |
| 39 | DNTH Dianthus Therapeutics, Inc. | 32,480 | $2.9M | 0.8% | -36.5% | 13F ↗ |
| 40 | INSM Insmed Incorporated · Com Par $.01 | 25,007 | $2.9M | 0.7% | -20.0% | 13F ↗ |
| 41 | UAL United Airlines Holdings, Inc. | 25,700 | $2.9M | 0.7% | New | 13F ↗ |
| 42 | EDIT Editas Medicine, Inc. | 1.11M | $2.8M | 0.7% | New | 13F ↗ |
| 43 | RBLX Roblox Corporation | 65,200 | $2.8M | 0.7% | New | 13F ↗ |
| 44 | MBX MBX Biosciences, Inc. | 46,709 | $2.7M | 0.7% | +301% | 13F ↗ |
| 45 | AVTX Avalo Therapeutics, Inc. | 176,673 | $2.7M | 0.7% | +44.1% | 13F ↗ |
| 46 | CGEM Cullinan Therapeutics, Inc. | 173,895 | $2.7M | 0.7% | New | 13F ↗ |
| 47 | XENE Xenon Pharmaceuticals Inc. | 70,908 | $2.6M | 0.7% | +101% | 13F ↗ |
| 48 | OCUL Ocular Therapeutix, Inc. | 336,251 | $2.6M | 0.7% | -17.7% | 13F ↗ |
| 49 | V Visa Inc. | 7,141 | $2.6M | 0.7% | +19.8% | 13F ↗ |
| 50 | CLDX Celldex Therapeutics, Inc. | 77,544 | $2.5M | 0.7% | -10.8% | 13F ↗ |
Showing the top 50 of 136 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
24 new, 48 added to, 63 trimmed, 35 exited, 1 unchanged. By estimated dollars.
New positions (24)
| GMAB Genmab A/S · ADR | 226,098 | New | $8.1M |
| MANE Veradermics, Incorporated | 54,232 | New | $6.6M |
| CTNM Contineum Therapeutics, Inc. | 217,788 | New | $2.9M |
| UNP Union Pacific Corporation | 10,584 | New | $2.9M |
| UAL United Airlines Holdings, Inc. | 25,700 | New | $2.9M |
| EDIT Editas Medicine, Inc. | 1.11M | New | $2.8M |
| RBLX Roblox Corporation | 65,200 | New | $2.8M |
| CGEM Cullinan Therapeutics, Inc. | 173,895 | New | $2.7M |
| TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 69,786 | New | $2.5M |
| FLEX Flex Ltd. | 16,297 | New | $1.8M |
Added to (48)
| EWTX Edgewise Therapeutics, Inc. | 160,647 | +76.5% | $2.8M |
| META Meta Platforms, Inc. | 4,512 | +288% | $2.4M |
| VRDN Viridian Therapeutics, Inc. | 272,610 | +70.5% | $2.3M |
| TLN Talen Energy Corporation | 15,151 | +85.9% | $2.2M |
| MBX MBX Biosciences, Inc. | 46,709 | +301% | $2.1M |
| MU Micron Technology, Inc. | 3,056 | +143% | $1.9M |
| CMPS COMPASS Pathways Plc · ADR | 508,780 | +37.1% | $1.7M |
| APH Amphenol Corporation | 29,530 | +155% | $1.5M |
| XENE Xenon Pharmaceuticals Inc. | 70,908 | +101% | $1.3M |
| VST Vistra Corp. | 13,965 | +185% | $1.3M |
Trimmed (63)
| AMLX Amylyx Pharmaceuticals, Inc. | 153,515 | -60.2% | -$6.8M |
| PRAX Praxis Precision Medicines, Inc. | 11,091 | -63.3% | -$5.6M |
| DFTX Definium Therapeutics, Inc. | 109,086 | -55.1% | -$5.1M |
| RVMD Revolution Medicines, Inc. | 45,897 | -31.5% | -$4.3M |
| CYTK Cytokinetics, Incorporated | 28,578 | -63.4% | -$3.3M |
| MAZE Maze Therapeutics, Inc. | 19,593 | -85.7% | -$3.2M |
| ABVX Abivax SA · ADR | 87,057 | -23.0% | -$2.6M |
| SYRE Spyre Therapeutics, Inc. | 50,414 | -35.2% | -$2.4M |
| IMVT Immunovant, Inc. | 205,954 | -25.9% | -$2.4M |
| KOD Kodiak Sciences Inc | 15,696 | -61.3% | -$2.4M |
Exited (35)
| ALMS Alumis Inc. | 199,968 | Exited | -$5.6M |
| MLYS Mineralys Therapeutics, Inc. | 86,085 | Exited | -$2.3M |
| EYPT EyePoint, Inc. | 155,704 | Exited | -$2.2M |
| RBC RBC Bearings Incorporated | 3,223 | Exited | -$2.1M |
| RKT Rocket Companies, Inc. | 125,530 | Exited | -$2.0M |
| TXN Texas Instruments Incorporated | 6,500 | Exited | -$1.9M |
| KBR KBR, Inc. | 54,206 | Exited | -$1.9M |
| FLS Flowserve Corporation | 24,958 | Exited | -$1.9M |
| ON ON Semiconductor Corporation | 18,200 | Exited | -$1.7M |
| NUE Nucor Corporation | 7,600 | Exited | -$1.7M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 136 | $380.9M | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 147 | $438.6M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 156 | $362.2M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 145 | $388.3M | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 148 | $408.0M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 146 | $272.1M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 148 | $259.5M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer